151 related articles for article (PubMed ID: 19005461)
1. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
Sachse-Seeboth C; Pfeil J; Sehrt D; Meineke I; Tzvetkov M; Bruns E; Poser W; Vormfelde SV; Brockmöller J
Clin Pharmacol Ther; 2009 Mar; 85(3):273-6. PubMed ID: 19005461
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
3. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies.
Sipeky C; Lakner L; Szabo M; Takacs I; Tamasi V; Polgar N; Falus A; Melegh B
Blood Cells Mol Dis; 2009; 43(3):239-42. PubMed ID: 19541511
[TBL] [Abstract][Full Text] [Related]
4. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Drug Metab Dispos; 2004 May; 32(5):484-9. PubMed ID: 15100169
[TBL] [Abstract][Full Text] [Related]
5. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.
Vormfelde SV; Brockmöller J; Bauer S; Herchenhein P; Kuon J; Meineke I; Roots I; Kirchheiner J
Clin Pharmacol Ther; 2009 Jul; 86(1):54-61. PubMed ID: 19369937
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9 gene and susceptibility to major depressive disorder.
LLerena A; Berecz R; Dorado P; González AP; Peñas-LLedó EM; De La Rubia A
Pharmacogenomics J; 2003; 3(5):300-2. PubMed ID: 14583800
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
Ma J; Yang XY; Qiao L; Liang LQ; Chen MH
J Dig Dis; 2008 May; 9(2):79-83. PubMed ID: 18419640
[TBL] [Abstract][Full Text] [Related]
10. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
11. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin.
Bland TM; Haining RL; Tracy TS; Callery PS
Biochem Pharmacol; 2005 Oct; 70(7):1096-103. PubMed ID: 16112652
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.
Karaźniewicz-Łada M; Luczak M; Główka F
Xenobiotica; 2009 Jun; 39(6):476-85. PubMed ID: 19480553
[TBL] [Abstract][Full Text] [Related]
13. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
15. Left ventricular non-compaction associated with a genetic variant of the CYP2C9 gene.
Bohrer T; Klein HG; Elert O
Heart Lung Circ; 2006 Aug; 15(4):269-71. PubMed ID: 16580879
[TBL] [Abstract][Full Text] [Related]
16. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
Yildirim H; Tamer L; Sucu N; Atik U
Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
[TBL] [Abstract][Full Text] [Related]
17. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
Zhou K; Donnelly L; Burch L; Tavendale R; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Lang CC; Palmer CN; Pearson ER
Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
[TBL] [Abstract][Full Text] [Related]
18. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH
Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
20. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.
Martínez C; García-Martín E; Blanco G; Gamito FJ; Ladero JM; Agúndez JA
Br J Clin Pharmacol; 2005 Jan; 59(1):62-9. PubMed ID: 15606441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
